Description
Consider this assay for an extensive analysis of key factors involved in angiogenesis and growth regulation. The Angiogenesis 12-Plex Panel (HDAGP17) simultaneously measures Angiopoietin-2, BMP-9, Endoglin, Endothelin-1, FGF-1, Follistatin, HB-EGF, HGF, Leptin, PLGF, VEGF-C, VEGF-D.
Indications:
Use this test to identify relevant therapy targets, determine disease mechanisms, and diagnose or monitor the following conditions associated with angiogenesis, vascular health, and tissue remodeling:
- Cancer: Evaluate tumor angiogenesis, progression, and response to therapy in various cancers, where biomarkers like Angiopoietin-2, VEGF-C, VEGF-D, HGF, and PLGF are involved in promoting new blood vessel formation and tumor growth.
- Cardiovascular Diseases: Assess cardiovascular conditions such as atherosclerosis, myocardial infarction, and heart failure. Biomarkers like Endothelin-1, BMP-9, Endoglin, and FGF-1 indicate vascular remodeling, endothelial dysfunction, and angiogenic activity.
- Chronic Wound Healing: Monitor chronic wound healing processes, including diabetic ulcers and venous leg ulcers. Biomarkers such as HB-EGF, FGF-1, and HGF are critical for tissue repair, cell proliferation, and angiogenesis.
- Pulmonary Diseases: Evaluate chronic lung diseases such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Biomarkers like VEGF-C, VEGF-D, and Follistatin indicate lung tissue remodeling and angiogenesis.
- Metabolic and Obesity-Related Disorders: Investigate metabolic syndrome, obesity, and related complications. Biomarkers such as Leptin and HGF are involved in metabolic regulation, inflammation, and angiogenesis.
- Peripheral Artery Disease (PAD): Assess the severity and progression of PAD, where biomarkers like Angiopoietin-2, Endothelin-1, and PLGF are indicative of angiogenic activity and vascular health.
- Neurological Disorders: Monitor neuroinflammatory and neurodegenerative conditions such as Alzheimer’s disease and multiple sclerosis, where biomarkers like VEGF-C and HB-EGF play roles in neuroprotection and angiogenesis.
Consider using the Long COVID Vascular Health 18-Plex Panel for the most comprehensive vascular health profile available.
Key Features:
- Comprehensive Biomarker Coverage: Provides a detailed analysis of 12 key biomarkers, ensuring a thorough diagnostic approach.
- CLIA Certified for Clinical Use: As a CLIA certified laboratory, we provide a panel that meets the highest standards of accuracy and reliability for clinical diagnostics.
- Versatility: Use this test to assess abnormalities of angiogenesis in cancer, autoimmune diseases, cardiovascular disease, or other chronic inflammatory conditions.
- Reference intervals: Are available for PLASMA-EDTA.
- Affordable Assay Services: We offer some of the most affordable assay services available, making advanced diagnostics accessible for clinical applications.
- Swift and Reliable Turnaround Time: We pride ourselves on a rapid turnaround time, with results typically delivered within 5 business days of receiving your specimen and payment.
Discover the power of precision with our Angiogenesis 12-Plex Panel, expertly designed for the Luminex® 200™ platform. This cutting-edge technology enables the simultaneous detection of multiple biomarkers from a minimal single sample, delivering comprehensive insights with unmatched efficiency.
Certified Excellence in Diagnostic Testing
Eve Technologies is certified by the Centers for Medicare & Medicaid Services (CMS) as a High Complexity International Laboratory under the Clinical Laboratory Improvement Amendments (CLIA), specializing in Diagnostic Immunology with a subspecialty in General Immunology (CLIA# 99D2283230). Additionally, we hold a clinical and public health laboratory license with the California Department of Public Health (COS-90013367). Our certification underscores our commitment to rigorous standards.
Clinicians: Please check with your State Agency to determine if additional licensure or registration requirements may apply.
Regulated tests: Ensuring Quality and Accuracy
The LDT (Lab Developed Test) designation highlights that our tests are regulated by the Centers for Medicare & Medicaid Services (CMS) under CLIA, ensuring they meet stringent quality and accuracy standards. Unlike commercially distributed tests, which undergo FDA approval, our LDTs are developed and validated within our laboratory to provide specialized and reliable diagnostic insights tailored to your needs. This distinction underscores our commitment to maintaining the highest standards in testing and personalized care.
! The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Biomarker levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions. ​